摘要
浆母细胞淋巴瘤(plasmablastic lymphoma,PBL)起源于生发中心终末分化期的活化B细胞,具有独特的临床、病理及分子学特征,呈现高度侵袭性、预后较差。PBL发病率低,诊断具有挑战性,治疗缺乏规范性。为加强我国临床医师对PBL的认识,提高诊断及治疗水平,有助于推动开展多中心临床研究,中华医学会血液学分会淋巴细胞疾病学组、中国临床肿瘤学会(CSCO)淋巴瘤专家委员会组织相关专家,讨论并形成本共识。
Plasmablastic lymphoma(PBL)originates from activated B cells in the terminal differentiation stage of the germinal centers.PBL is characterized by unique clinical,pathological,and molecular features,demonstrating high aggressiveness and poor prognosis.It exhibits a low incidence and a challenging diagnosis,with a lack of standardized treatment protocols.To improve the understanding of PBL among clinical physicians in China and enhance diagnostic and treatment levels,which will facilitate the initiation of multicenter clinical research,the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Lymphoma Expert Committee of the Chinese Society of Clinical Oncology(CSCO)have organized relevant experts to formulate this consensus.
作者
中华医学会血液学分会淋巴细胞疾病学组
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会
徐兵
赵维莅
马军
Lymphoid Disease Group,Chinese Society of Hematology,Chinese Medical Association;Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Xu Bing;Zhao Weili;Ma Jun(不详;Department of Hematology,the First Affiliated Hospital of Xiamen University and Institute of Hematology,School of Medicine,Xiamen University,Xiamen Hematology Medical Quality Control Center,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy,Xiamen 361003,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Harbin Institute of Hematology&Oncology,Harbin 150010,China)
出处
《中华血液学杂志》
北大核心
2025年第4期295-301,共7页
Chinese Journal of Hematology
